Design, synthesis and evaluation of substituted N-(3-arylpropyl)-9,10- dihydro-9-oxoacridine-4-carboxamides as potent MDR reversal agents in cancer

Chinese Journal of Chemistry

Volumn 29, Issue 3, 2011, Pages 504-510

  Velingkar, V S ^a   Dandekar, V D ^a  

^a PRIN K M KUNDNANI COLLEGE OF PHARMACY   (India)

Author keywords

10 dihydro 9 oxo acridine 4 carboxamides; MDR reversal agents; N (3 arylpropyl) 9; Pharmacophore; Phase drug design software; Structure elucidation; Structure activity relationships

Indexed keywords

EID: 79953234389     PISSN: 1001604X     EISSN: 16147065     Source Type: Journal    
DOI: 10.1002/cjoc.201190113     Document Type: Article

References (12)

1. Krishna, R.; Mayer, L. D. Eur. J. Pharm. Sci. 2000, 11, 265.
2. Ferry, D. R.; Traunecker, H.; Kerr, D. J. Eur. J. Cancer 1996, 32A, 1070.
3. Ford, J. M.; Hait, W. N. Pharmacol. Rev. 1990, 42,155.
4. Thomas, H.; Coley, H. M. Cancer Control 2003, 10,159.
5. Wandel, C.; Kim, R. B.; Kajiji, S. Cancer Res. 1999, 59, 3944.
6. Twentyman, P. R.; Bleehen, N. M. Eur. J. Cancer 1991, 27, 1639.
7. Dantzig, A. H.; Shepard, R. L.; Law, K. L. J. Pharmacol. Exp. Ther. 1999, 290, 854.
8. Roe, M.; Folkes, A.; Ashworth, P. Bioorg. Med. Chem. Lett. 1999, 9, 595.
9. Dodic, N.; Dumaitre, B.; Daugan, A.; Pianetti, P. J. Med. Chem.1995, 38, 2418.
10. Joshi, J. K.; Patel, V. R.; Patel, K.; Rana, D.; Shah, K.; Patel, R. Ind. J. Pharm. Sci. 2007, 69, 697.
11. Atwell, G. J.; Cain, B. F.; Baguley, B. C.; Finlay, G. J.; Denny, W. A. J. Med. Chem. 1984, 27, 1481.
12. Muller, H.; Pajeva, I. K.; Globischa, C.; Wiese, M. Bioorg. Med. Chem. 2008, 16, 2456.